Biogen Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| BIIB.MX | AMGN | LLY | 0QYQ.IL | BMY | NVS.BA | |
|---|---|---|---|---|---|---|
| Market cap | 693.22B | 258.68B | 1.26T | 219.86B | 131.21B | 65.30T |
| P/E (TTM) | 115.0 | 27.7 | 46.0 | 40.6 | 14.2 | 4.6 |
| Forward P/E | — | 19.5 | 28.3 | — | 9.6 | — |
| Price/book | 2.0 | 18.0 | 31.4 | 10.4 | 5.6 | 2.3 |
| Dividend yield | — | 2.11% | 0.49% | 3.81% | 3.93% | 2.40% |
| 1-year change | +68.09% | +51.61% | +51.26% | +40.64% | +37.66% | +41.41% |
| Today | 0.00% | +3.73% | +0.61% | +2.59% | +4.02% | +4.22% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All BIIB.MX news ›Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites Trial advances FT819 toward a potential accelerated regulatory pathway supported by RMAT…
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with slowing of clinical…
Stifel Nicolaus Sticks to Their Buy Rating for Biogen (BIIB)
Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen yesterday and set a price target of $286.00. Matteis covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Contineum Therapeutics, Inc. Class A, and…
Biogen (BIIB) Receives a Buy from Needham
In a report released today, Ami Fadia from Needham reiterated a Buy rating on Biogen, with a price target of $290.00. According to TipRanks, Fadia is a 5-star analyst with an average return of 30.0% and a 54.46% success rate. Fadia covers…
UBS Remains a Buy on Biogen (BIIB)
UBS analyst Michael Yee maintained a Buy rating on Biogen today and set a price target of $300.00. Yee covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb. According to TipRanks,…
Morgan Stanley Issues Positive Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price
Posted by Defense World Staff on Oct 31st, 2026 BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price lifted by Morgan Stanley from $87.00 to $88.00 in a research note issued to investors on Friday morning,Benzinga reports. The…
Denali Therapeutics price target raised to $34 from $31 at Baird
Baird raised the firm’s price target on Denali Therapeutics (DNLI) to $34 from $31 and keeps an Outperform rating on the shares. The firm update... Denali Therapeutics price target raised to $34 from $31 at Baird Baird raised the firm’s…
Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Denali Therapeutics (DNLI) to $40 from $36 and keeps an Overweight rating o... Denali Therapeutics price target raised to $40 from $36 at Morgan Stanley Morgan Stanley…
Denali Therapeutics price target raised to $35 from $30 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Denali Therapeutics (DNLI) to $35 from $30 and keeps a Buy rating on the share... Denali Therapeutics price target raised to $35 from $30 at B. Riley B. Riley analyst Mayank…
Biogen Earnings: Revenue Pillars Shifting Toward Growth Drugs
Biogen is shifting its revenue pillars from its former mainstay multiple sclerosis (MS) treatments to drugs for Alzheimer's disease and rare diseases. In its earnings reports, the company discloses the former as legacy products and the…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com41
- themarketsdaily.com23
- markets.businessinsider.com20
- seekingalpha.com16
- theglobeandmail.com16
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 120 articles, not a forecast.